A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration 

Nov 08 2025
Convention Center: Room 151, Level 1
12:30 PM - 2:00 PM

World Class Speakers

Naim Alkhouri, MD, FAASLD
Industry Presenter

Naim Alkhouri, MD, FAASLD

Summit Clinical Research
Meena B Bansal, MD, FAASLD
Industry Presenter

Meena B Bansal, MD, FAASLD

Icahn School of Medicine at Mount Sinai (ISMMS)
Rohit Loomba, MD, MHSc, FAASLD
Industry Presenter

Rohit Loomba, MD, MHSc, FAASLD

University of California, San Diego

Description

Join our experts as they discuss practical aspects of integrating liver-directed therapy for the treatment of MASH. Listen as they discuss real-world successes and challenges with using THR-B agonists and GLP-1RAs. Catch up on the latest data on noninvasive testing and other treatments in late-stage development. 

Supported by: Madrigal Pharmaceuticals

Organized by: AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Link: https://www.eventbrite.com/e/a-new-era-in-mash-how-disease-specific-therapies-are-changing-the-game-tickets-1564244961789?aff=oddtdtcreator

Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Journey Maps

Objectives

  • Upon successful completion of this activity, participants should be better able to: Describe the mechanistic and clinical rationale for THR-b agonists as a means of treating MASLD/MASH
  • Evaluate the evidence on THR-b agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
  • Identify best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
  • Develop guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios